MI-773 (SAR405838)

Catalog No.S7649 Batch:S764902

Print

Technical Data

Formula

C29H34Cl2FN3O3

Molecular Weight 562.50 CAS No. 1303607-60-4
Solubility (25°C)* In vitro DMSO 100 mg/mL (177.77 mM)
Ethanol 31 mg/mL (55.11 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
Targets
MDM2 [1]
(Cell-free assay)
MDM2 [1]
0.88 nM(Ki) 8.2 nM(Kd)
In vitro MI-773 binds to MDM2 with Ki of 0.88 nM. MI-773 potently inhibits cell growth in cancer cell lines, including SJSA-1 (IC50, 0.092 μM), RS4;11 (IC50, 0.089 μM), LNCaP (IC50, 0.27 μM), and HCT-116 (IC50, 0.20 μM) cells, and displays high selectivity over cancer cell lines with mutated or deleted p53, including SAOS-2 (IC50, >10 μM), PC-3 (IC50, >10 μM), SW620 (IC50, >10 μM), and HCT-116 (p53-/-) (IC50, >20 μM) cells. [1]
In vivo In the SJSA-1 osteosarcoma, acute lymphoblastic leukemia RS4;11, LNCaP prostate cancer, and HCT-116 colon cancer xenograft model, MI-773 (p.o.) effectively inhibits tumor growth in a dose-dependent manner (10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg,). [1]

Protocol (from reference)

Kinase Assay:[1]
  • Fluorescence-polarization binding assay

    Binding affinities of MDM2 inhibitors and p53 peptide to MDM2 protein are determined using an Fluorescence-polarization (FP) binding assay. Binding affinities of MI-773 to Bcl-2, Bcl-xL, Mcl-1, and β-catenin are determined using a competitive FP-based assay, and its binding affinity to MDMx is determined using Biolayer Interferometry technology.

Cell Assay:[1]
  • Cell lines

    SJSA-1, RS4;11, LNCaP, SAOS-2, PC-3, SW620, HCT-116, and HCT-116 (p53-/-) cells

  • Concentrations

    100 μM

  • Incubation Time

    ~48 h

  • Method

    Cell growth inhibition activity is determined in a water-soluble tetrazolium-based assay. Cell death is measured by trypan blue staining and apoptosis is determined using an Annexin V-FLUOS staining kit.

Animal Study: [1]
  • Animal Models

    SCID mice with SJSA-1 osteosarcoma (females), acute lymphoblastic leukemia RS4;11 (females), LNCaP prostate cancer (males), or HCT-116 colon cancer (females) xenograft model

  • Dosages

    200 mg/kg

  • Administration

    p.o.

Customer Product Validation

Data from [Data independently produced by , , Oncotarget, 2016, 7(50):82757-82769]

Selleck's MI-773 (SAR405838) has been cited by 14 publications

High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma [ Pharmaceutics, 2023, 15(4)1274] PubMed: 37111759
BCL6 inhibition ameliorates ruxolitinib resistance in CRLF2-rearranged acute lymphoblastic leukemia [ Haematologica, 2022, 10.3324/haematol.2022.280879] PubMed: 36005560
LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression [ Oncogenesis, 2022, 11(1):37] PubMed: 35780125
Nucleotide biosynthesis links glutathione metabolism to ferroptosis sensitivity [ Life Sci Alliance, 2022, 5(4)e202101157] PubMed: 35074928
Compartmentalization-aided interaction screening reveals extensive high-order complexes within the SARS-CoV-2 proteome [ Cell Rep, 2021, 36(5):109482] PubMed: 34297909
Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers [ NPJ Precis Oncol, 2021, 5(1):96] PubMed: 34711913
Paracrine Placental Growth Factor Signaling in Response to Ionizing Radiation Is p53-Dependent and Contributes to Radioresistance [ Mol Cancer Res, 2021, 19(6):1051-1062] PubMed: 33619227
MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1 [ Oncol Lett, 2021, 22(6):838] PubMed: 34712362
MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models [ Cancers (Basel), 2020, 12(8):E2157] PubMed: 32759684
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses [ EMBO J, 2019, 38(20):e102096] PubMed: 31483066

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.